<PAGE>
U. S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
(Mark one)
/X/ Quarterly Report Under Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the quarterly period ended July 31, 2000
or
/ / Transition Report Under Section 13 or 15(d) of the Securities
Exchange Act of 1934
Commission File Number: 33-23460-LA
AQUASEARCH, INC.
(Exact name of small business issuer as specified in its charter)
Colorado 33-0034535
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
73-4460 Queen Ka'ahumanu Highway, Suite 110
Kailua-Kona, Hawaii 96740
(Address of principal executive offices)
(808) 326-9301
(Issuer's telephone number, including area code)
NOT APPLICABLE
(Former name, former address and former fiscal
year, if changes since last report)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
YES X NO
--- ---
As of July 31, 2000, the number of shares outstanding of issuer's common stock,
$0.0001 par value, was 103,984,615 shares.
<PAGE>
Aquasearch, Inc.
Form 10-QSB For The
Quarter Ended July 31, 2000
Contents
PART I - FINANCIAL INFORMATION
<TABLE>
<CAPTION>
Page
<S> <C>
Item 1: Financial Statements
Condensed Balance Sheets 3
Condensed Statements of Operations 4, 5
Condensed Statements of Cash Flows 6
Notes to Condensed Financial Statements 7
Item 2: Management's Plan of Operation
Overview 8
Management's Plan of Operation for the Next Twelve Months 19
Management's Discussion and Analysis of Financial Condition
and Results of Operations 28
PART II - OTHER INFORMATION
Item 1: Legal Proceedings 30
Item 2: Changes In Securities 31
Item 3. Defaults Upon Senior Securities 31
Item 4: Submission of Matters to a Vote of Security Holders 31
Item 5: Other Information 31
Item 6: Exhibits And Reports on Form 8-K 31
</TABLE>
2
<PAGE>
AQUASEARCH, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED BALANCE SHEETS
<TABLE>
<CAPTION>
July 31, October 31,
2000 1999
(Unaudited) (Audited)
-----------------------------------------
<S> <C> <C>
Assets
Current assets:
Cash $ 135,667 $ 90,522
Accounts receivable 19,036 24,300
Prepaid expenses 10,400 11,507
Refundable deposits 7,524 3,053
-----------------------------------------
Total current assets 172,627 129,382
-----------------------------------------
Note receivable from officer 50,000 50,000
Plant and equipment:
Plant 2,842,517 2,795,258
Equipment 1,046,826 1,060,348
Less accumulated depreciation (597,690) (413,244)
-----------------------------------------
Net plant and equipment 3,291,653 3,442,362
-----------------------------------------
Total assets $ 3,514,280 $ 3,621,744
=========================================
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 988,021 $ 894,995
Due to officer 297,000 241,800
Notes payable 25,000 170,000
Notes payable to officer 969,715 1,830,000
-----------------------------------------
Total current liabilities 2,279,736 3,136,795
-----------------------------------------
Stockholders' equity
Preferred stock (5,000,000 shares authorized) - -
Common stock ($0.0001 par value, 150,000,000 shares
authorized, 103,984,615 and 87,060,501 shares
outstanding at July 31, 2000 and
October 31, 1999, respectively) 11,519 9,829
Additional paid-in capital 16,498,886 12,262,839
Notes receivable (58,133) (58,133)
Deficit accumulated during the development stage (15,217,728) (11,729,586)
-----------------------------------------
Total stockholders' equity 1,234,544 484,949
-----------------------------------------
Total liabilities and stockholders' equity $ 3,514,280 $ 3,621,744
=========================================
</TABLE>
3
<PAGE>
AQUASEARCH, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
For the Period For the Three For the Three
From Inception Months Ended Months Ended
To July 31, July 31, July 31,
2000 2000 1999
(Unaudited) (Unaudited) (Unaudited)
-----------------------------------------------------------
<S> <C> <C> <C>
Operations
Sales $ 11,077 $ - $ -
Cost of sales 23,464 - -
-----------------------------------------------------------
Gross loss from operations (12,387) - -
Research and development costs 6,615,589 721,748 515,318
General and administrative expenses 6,804,122 565,106 366,945
-----------------------------------------------------------
Loss from operations (13,432,098) (1,286,854) (882,263)
Other income (expense)
Interest (1,844,900) (90,604) (116,528)
Other 220,868 43,260 7,227
Investment in joint venture (147,096) - -
-----------------------------------------------------------
Total other income (expense) (1,771,128) (47,344) (109,301)
-----------------------------------------------------------
Loss before income taxes and extraordinary
item (15,203,226) (1,334,198) (991,564)
Extraordinary item - loss on write down of
assets to liquidation basis (14,502) - -
-----------------------------------------------------------
Net loss $ (15,217,728) $ (1,334,198) $ (991,564)
===========================================================
Loss per share $ (0.51) $ (0.01) $ (0.01)
===========================================================
Weighted average shares outstanding 29,987,669 103,259,590 71,283,181
===========================================================
</TABLE>
4
<PAGE>
AQUASEARCH, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
For the Period From For the Nine For the Nine
Inception Months Ended Months Ended
To July 31, July 31, July 31,
2000 2000 1999
(Unaudited) (Unaudited) (Unaudited)
-----------------------------------------------------------
<S> <C> <C> <C>
Operations
Sales $ 11,077 $ - $ -
Cost of sales 23,464 - -
-----------------------------------------------------------
Gross loss from operations (12,387) - -
Research and development costs 6,615,589 1,832,571 1,206,523
General and administrative expenses 6,804,122 1,362,127 1,505,162
-----------------------------------------------------------
Loss from operations (13,432,098) (3,194,698) (2,711,685)
Other income (expense)
Interest (1,844,900) (470,685) (558,687)
Other 220,868 177,241 6,829
Investment in joint venture (147,096) - -
-----------------------------------------------------------
Total other income (expense) (1,771,128) (293,444) (551,858)
-----------------------------------------------------------
Loss before income taxes and extraordinary
item (15,203,226) (3,488,142) (3,263,543)
Extraordinary item - loss on write down of
assets to liquidation basis (14,502) - -
-----------------------------------------------------------
Net loss $ (15,217,728) $ (3,488,142) $ (3,263,543)
===========================================================
Loss per share $ (0.51) $ (0.04) $ (0.05)
===========================================================
Weighted average shares outstanding 29,987,669 99,177,707 71,283,181
===========================================================
</TABLE>
5
<PAGE>
AQUASEARCH, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
For the Period For the Nine For the Nine
From Inception Months Ended Months Ended
To July 31, July 31, July 31,
2000 2000 1999
(Unaudited) (Unaudited) (Unaudited)
---------------------------------------------------------
<S> <C> <C> <C>
Cash flows from operating activities
Net loss $(15,217,728) $ (3,488,142) $ (3,263,543)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation 597,690 184,446 152,461
Expenses paid with common stock 1,121,756 166,617 41,981
Discount on convertible notes payable 1,445,976 362,482 441,141
Changes in:
Other current assets (17,924) (3,364) 26,434
Receivables (19,036) 5,264 (6,131)
Accounts payable and due to officer 1,285,021 148,226 310,537
---------------------------------------------------------
Cash used in operating activities (10,804,245) (2,624,471) (2,297,120)
Cash flows from investing activities
Purchases of fixed assets (3,889,343) (33,737) (1,195,592)
---------------------------------------------------------
Cash used in investing activities (3,889,343) (33,737) (1,195,592)
Cash flows from financing activities
Increase in notes receivable (48,437) - 1,563
Proceeds from issuance of common stock 5,986,033 544,575 500,000
Proceeds from notes payable 9,268,863 2,264,063 2,914,800
Repayment of notes payable (105,285) (105,285) -
Offering costs (271,919) - -
---------------------------------------------------------
Cash provided by financing activities 14,829,255 2,703,353 3,416,363
---------------------------------------------------------
Net increase in cash 135,667 45,145 (76,349)
Cash, beginning of the period - 90,522 151,473
---------------------------------------------------------
Cash, end of the period $ 135,667 $ 135,667 $ 75,124
=========================================================
Supplemental disclosure of cash flow information:
Non-cash financining transactions:
Conversion of convertible notes
payable to common stock $ 8,168,863 $ 3,164,063 $ 1,929,800
</TABLE>
6
<PAGE>
AQUASEARCH, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS
JULY 31, 2000
(UNAUDITED)
1. GENERAL
The accompanying unaudited financial statements have been prepared in accordance
with generally accepted accounting principles for interim financial information
and with the instructions to Form 10-QSB. Accordingly, they do not include all
of the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management, all
adjustments (consisting of normal recurring adjustments) considered necessary
for a fair presentation have been included.
These financial statements should be read in conjunction with the financial
statements in our Annual Report on Form 10-KSB for the year ended October 31,
1999.
2. COMMON STOCK AND COMMON STOCK PURCHASE WARRANTS
An analysis of the changes in stockholders' equity is as follows:
<TABLE>
<CAPTION>
Shares of Additional Total
Common Common Paid-In Notes Accumulated Stockholders'
Stock Stock Capital Receivable Deficit Equity
-----------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Balance, April 30, 2000 101,341,457 $ 11,256 $15,735,582 $ (58,133) $ (13,883,530) $1,805,175
Issuance of stock upon
conversion of convertible
notes payable ($0.14 to
$0.62 per share) 2,462,193 245 645,339 - - 645,584
Sale, grants, and issuance of
stock upon exercise of
stock options ($0.25 to
$0.58 per share) 180,965 18 50,895 - - 50,913
Discount on convertible notes
payable - - 67,070 - - 67,070
Loss for the three months
ended July 31, 2000 - - - - (1,334,198) (1,334,198)
-----------------------------------------------------------------------------------------
Balance, July 31, 2000 103,984,615 $ 11,519 $16,498,886 $ (58,133) $ (15,217,728) $1,234,544
=============== =========== ============== ============= ================ ===============
</TABLE>
Discount on notes payable of $67,070 results from the difference between the
conversion price and the fair value of the common stock underlying the
convertible notes on their respective issuance dates for convertible notes
issued during the quarter ended July 31, 2000.
7
<PAGE>
AQUASEARCH, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS
JULY 31, 2000
(UNAUDITED)
The following is a summary of our common stock purchase warrants for the quarter
ended July 31, 2000:
<TABLE>
<CAPTION>
Exercise Outstanding at Outstanding at
Price April 30, 2000 Issued Exercised July 31, 2000
---------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
$0.21 25,974 - - 25,974
$0.40 1,100,000 - - 1,100,000
$0.50 6,346,513 431,912 - 6,778,425
$0.75 122,291 445,795 - 568,086
$1.00 260,000 229,249 - 489,249
$1.50 154,599 - - 154,599
$2.00 79,491 - - 79,491
---------------------------------------------------------------------------------------
8,088,868 1,106,956 - 9,195,824
=======================================================================================
</TABLE>
At July 31, 2000, we had reserved a sufficient number of shares of our common
stock for issuance upon exercise of the warrants.
ITEM 2. MANAGEMENT'S PLAN OF OPERATION
The following discussion of our management's plan of operation contains certain
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, including statements that indicate what we
"believe," "expect" and "anticipate" or similar expressions. These statements
involve known and unknown risks, uncertainties and other factors which may cause
our actual results, performance or achievements to differ materially from those
expressed or implied by such forward-looking statements. Such factors include,
among others, the information contained under the caption "Factors That May
Affect Future Operating Results" in our Annual Report on Form 10-KSB for the
year ended October 31, 1999. You should not place undue reliance on these
forward-looking statements, which reflect our management's analysis only as of
the date of this quarterly report on Form 10-QSB. We undertake no obligation to
publicly release the results of any revision of these forward-looking
statements. You are strongly urged to read the information set forth under the
caption "Factors That May Affect Future Operating Results" in the October 31,
1999 Form 10-KSB for a more detailed description of these significant risks and
uncertainties.
OVERVIEW
We are a development stage company that develops and commercializes natural
products from microalgae using our proprietary photobioreactor technology known
as the Aquasearch Growth Module, or AGM.
Microalgae are a diverse group of over 30,000 species of microscopic plants that
have a wide range of physiological and biochemical characteristics. Microalgae
produce many different and unusual fats,
8
<PAGE>
sugars, proteins, amino acids, vitamins, enzymes, pigments and other bioactive
compounds that have existing and potential commercial applications in such
fields as animal and human nutrition, food colorings, cosmetics, diagnostic
products, pharmaceuticals, research grade chemicals, pigments and dyes.
Microalgae grow ten times faster than the fastest growing land-based crops and
represent a largely unexploited and renewable natural resource with a
biodiversity comparable to that of land-based plants.
Although microalgae are believed to be a potential source for many valuable
commercial applications, less than 5,000 species of microalgae have ever been
isolated from nature, and fewer than 10 species of microalgae - less than
one-tenth of one percent of all such species - have ever been cultivated
commercially.
We believe that the development of a large biotechnology industry, based on
thousands of species of microalgae, has been impeded only by a lack of
technology. We anticipate that our commercial production technology will allow
us to create a market for new and valuable substances derived from microalgae.
Our company, since its inception, has been dedicated to this proposition.
Achievements in the past 20 months include major advances in our platform
technology, the AGM. During this time period, we have:
- created the new "Ultra-AGM," which has six-fold greater capacity
than the previous AGM model - an increase from 1,060 to 6,600
gallons;
- tripled the capacity-per-unit-cost of the AGM;
- tripled the productivity-per-unit-capacity of HAEMATOCOCCUS - our
astaxanthin-rich microalgae; and
- doubled the astaxanthin content of HAEMATOCOCCUS - from 1.5% to
3.0%.
During the same time period, we have:
- tripled the size of our production facility;
- quadrupled our patents - from three to twelve;
- tripled our total production capacity;
- initiated sales of our products;
- expanded our product pipeline to include nutraceuticals and
pharmaceuticals;
- strengthened our management team in areas of strategic development
and marketing; and
- augmented our research team in natural products chemistry and drug
development.
In the past year we focused primarily on technology and infrastructure. Our
current focus includes marketing, sales, and further expanding our product
pipeline.
HISTORY: KEY EVENTS
1984
AQUASEARCH FOUNDED. Scientists from Scripps Institution of Oceanography
in La Jolla, California founded Aquasearch, Inc. as a California
corporation.
1988
FEB: We incorporated Aquasearch, Inc. in Colorado.
9
<PAGE>
MAY: Aquasearch (Colorado) acquired all the assets of Aquasearch
(California) in a stock-for-stock exchange.
JUN: OPERATIONS BEGIN in Borrego Springs, California.
1988-1993
RESEARCH AND DEVELOPMENT. We developed our first prototype of the AGM.
Over the next few years we refined certain details of engineering in
the AGM. At the same time, we cultivated microalgal species of markedly
different varieties.
1993
MAR: AQUASEARCH-CYANOTECH JOINT VENTURE FORMED. We formed a joint
venture company with Cyanotech, an unaffiliated producer of
microalgae. Our goal was to develop commercial systems for
producing astaxanthin-rich microalgae. We contributed
approximately $147,000 in capital and licensed our AGM
technology to the joint venture. Cyanotech contributed
approximately $15,000 in capital to the joint venture and made
available its facilities and personnel at the Hawaii Ocean
Science and Technology, or HOST, Business Park at Keahole
Point, Kailua-Kona, Hawaii.
1994
JUN: CULTOR NEGOTIATION BEGINS. We began discussions with Cultor
regarding the purchase of astaxanthin-rich microalgae.
JUL: FIRST ASTAXANTHIN PRODUCED. We constructed AGMs that
demonstrated the economics of the production process. We also
produced samples of astaxanthin-rich microalgae for analysis
and trial applications. Samples were sent to Cultor for
testing.
NOV: AQUASEARCH-CYANOTECH JOINT VENTURE TERMINATED. We decided to
discontinue the joint venture with Cyanotech. Under our
dissolution agreement, all intellectual property rights to AGM
technology reverted to us.
DEC: CULTOR STARTS FEEDING TRIALS on farmed salmon using the
astaxanthin-rich microalgae we produced.
1995
APR: CONSTRUCTION BEGINS on our own half-acre facility in Hawaii,
leased from the HOST Business Park. We designed the facility
for research and development, and for production of small
amounts of astaxanthin-rich microalgae for marketing.
JUN: CONSTRUCTION COMPLETED. Our first facility was comprised of
AGMs and an operating laboratory.
JUL: SVENSKA FODER CONTRACT. We entered into a three-year Supply
Agreement with Svenska Foder, then a subsidiary of Cultor.
Svenska Foder agreed to act as the exclusive distributor of our
natural astaxanthin product for animal feed applications in
Sweden, Norway and Finland. In December 1996, Cultor sold
Svenska Foder to KKR, a Danish animal feeds company, and
assumed all of Svenska Foder's rights and obligations under the
Supply Agreement.
FACILITY EXPANSION BEGINS. We leased additional space in the
HOST Business Park to
10
<PAGE>
expand our half-acre research and development facility to one
acre.
OCT: ONE-ACRE EXPANSION COMPLETED. We expanded the facility to
include finishing ponds (the second stage of our production
process), and additional laboratory space.
1996
MAY: CULTOR AGREEMENT. We entered into a three-year Distribution and
Development Agreement with Cultor (recently extended to four
years). We agreed to act as the exclusive worldwide supplier to
Cultor of natural astaxanthin derived from microalgae for
animal feed applications. Cultor agreed to act as the exclusive
worldwide distributor of our natural astaxanthin product for
animal feed applications.
SCIENTIFIC ADVISORY BOARD FORMED. We created an active
Scientific Advisory Board consisting of Ph.D.s with expertise
in the fields of aquaculture; marine biology; fluid dynamics;
and the chemistry, photobiology, physiology, genetics and mass
culture of microalgae.
JUL: PROCESS PATENT IN THE U.S. We were awarded U.S. Patent Number
5,541,056 for a "Method of Control of Microorganism Growth
Process." This patent claims certain processes that operate in
our proprietary, closed-system photobioreactor, the AGM. Our
U.S. filing was made under the Patent Cooperation Treaty. We
began to pursue international patents in certain treaty-member
nations.
OCT: CULTOR ACQUIRES AQUASEARCH STOCK. Cultor acquired 400,000
shares of our common stock at a purchase price of $0.50 per
share.
NOV: C. BREWER AGREEMENT. We executed a Letter of Intent with C.
Brewer and Company, Limited. Under the proposed agreement we
would acquire between 80 and 90 acres of C. Brewer property in
the Ka'u region of the Big Island of Hawaii, valued at between
$900,000 and $1,000,000. In return, C. Brewer would acquire
approximately 4% of our outstanding common stock and a
three-year warrant to purchase up to 500,000 shares of
Aquasearch common stock at $1.25 per share. To date, we have
not consummated the transaction with C. Brewer because
production at our current facility has increased beyond
expectation.
1997
APR: EARL FUSATO NAMED CHIEF FINANCIAL OFFICER, JOINS BOARD. Mr.
Fusato brought considerable experience to our management team.
At VeriFone, Inc., a global leader in the transaction
automation industry, he served as VP Finance (1983-87),
Treasurer (1987-90) and Director of Internal Audit and Manager
of Transaction Automation (1990-92). He served as CFO of RESCO
Inc., a residential real estate brokerage company (1992-94). He
also served in various key positions at Ernst and Young
(1978-83) and KPMG Peat Marwick (1971-77).
JUN: APPARATUS PATENT IN EUROPE. We were awarded European Patent
Number 0494887 for a "Process and Apparatus for the Production
of Photosynthetic Microbes." This patent not only claims
certain processes, but also certain features of our core
technology, the Aquasearch Growth Module. The European patent
complements, but does not supplant claims made in the U.S.
Patent awarded in 1996. Our European filing was made under the
Patent Cooperation Treaty. We are pursuing additional patents
in certain treaty-
11
<PAGE>
member nations.
SEP: DR. EDWARD DAVID JOINS BOARD. Dr. David has a long history of
management experience in the fields of science and technology.
During his career he has served as President of Exxon Research
and Engineering, Science Advisor to the President of the United
States, Executive Director of the Communications Systems
Division at Bell Laboratories, and Director of the White House
Office of Science and Technology Policy.
1998
APR: EXPANSION BEGINS TO TRIPLE OUR PRODUCTION FACILITY. We began
construction to expand our production facility in Kona, Hawaii
from one acre to three acres. At the same time, we began
upgrading every component of our production system hardware.
JUN: WE QUESTION CYANOTECH REGARDING INTELLECTUAL PROPERTY. We
formally notified Cyanotech of our concern that their use of
photobioreactor technology may violate one of our patents (U.S.
patent No. 5,541,056) relating to processes for controlling
microalgae growth. We also expressed concern regarding possible
trade secret misappropriation.
JUL: DAVID WATUMULL NAMED EXECUTIVE VP, CORPORATE FINANCE AND
STRATEGIC DEVELOPMENT. Mr. Watumull brought more strength to
our management team. He has been a respected biotechnology
industry analyst, investment banker and money manager for more
than 15 years, serving at both Paine Webber and First Honolulu
Securities.
WE TEST A NEW PHOTOBIOREACTOR - THE ULTRA-AGM. In previous
months we designed and engineered the Ultra-AGM. The Ultra-AGM
is more than six times larger than any standard production
growth module we have used. To our knowledge, the Ultra-AGM is
larger than any closed-system photobioreactor ever operated. A
six-month testing period begins.
CYANOTECH FILES LAWSUIT. Our former joint venture partner filed
a complaint in the United States District Court for the
District of Hawaii (Case No. CV98-00600ACK) against us.
Cyanotech sought a declaratory judgment of:
- invalidity of our U.S. patent for a method to grow
microalgae;
- non-infringement by Cyanotech of the U.S. patent; and
- non-misappropriation of our trade secrets regarding the
Aquasearch Growth Module.
SEP: WE COUNTER-SUE CYANOTECH. We asserted the validity of our U.S.
patent. We also alleged that Cyanotech:
- infringed our U.S. patent;
- misappropriated trade secrets related to our AGM
technology;
- breached our joint venture dissolution agreement; and
- engaged in unfair competition.
We requested damages, injunctive relief and attorney's fees on
each count.
12
<PAGE>
APPARATUS PATENT IN HONG KONG. We were awarded patent number
HK1001232 for the "Process and Apparatus for the Production of
Photosynthetic Microbes." This patent was awarded under the
Patent Cooperation Treaty, based on the original filing
approved by the European Patent Office in 1997.
NOV: CHARTER MEMBERSHIP IN MARBEC. The Marine Bioproducts
Engineering Center, or MarBEC, is a 5-year, $26 million
Engineering Research Center, funded by the U.S. National
Science Foundation. MarBEC is focused on developing new
enzymes, pigments and pharmaceuticals, primarily from
microalgae. It is based at the University of Hawaii and the
University of California, Berkeley. We are among the charter
industry members of MarBEC, which also include Monsanto and
Eastman Chemical. As a charter member, we have certain
preferential rights to new products developed by MarBEC. We are
the only member of MarBEC that has developed photobioreactor
technology, which we believe is likely to be required for the
commercial exploitation of any new product from microalgae.
DEC: ENZYMED AGREEMENT. We entered into a Compound Library Agreement
with EnzyMed, Inc., a privately-held biotechnology company
recently acquired by Albany Molecular Research, Inc. Under the
agreement, we will provide extracts of microalgae that contain
unexplored or unexploited substances with biomedical value.
EnzyMed will use these extracts to generate compounds using
their method of "combinatorial biocatalysis." This method
generally produces several hundred compounds from a single
extract. We expect some of these compounds to be novel and
proprietary. Both companies intend to commercialize the
resulting compound "libraries." Compound libraries are
typically screened for possible medical applications by the
pharmaceutical industry. The pharmaceutical company typically
pays an "access fee" for the right to screen the library for a
limited time and for limited applications. We will share the
revenues generated from the libraries with EnzyMed.
1999
JAN: MARTIN GUERIN NAMED VP, SALES AND MARKETING. Mr. Guerin has
international experience with world-leading groups in food and
feed industries. He held top management positions for marketing
and business development with Finfeeds International (1996-98)
and EWOS (1994-96), both Cultor companies. His previous
experience includes management positions with BP Nutrition (now
Nutreco) and Champagnes Cereales.
NEW EQUIPMENT INSTALLATION BEGINS. With construction nearly
complete on our expanded three-acre facility, we began to
install new equipment for process control and for final
processing of raw products.
THE ULTRA-AGM GOES INTO OPERATION. After a successful six-month
testing period, we installed and began to operate the new
Ultra-AGM. This new photobioreactor is much larger, more
efficient, and less costly than any previous AGM. It also
requires 75% less manpower to operate.
FEB: CONSTRUCTION COMPLETED ON THREE-ACRE PHYSICAL PLANT. We
completed all new structures at our production facility. We
tripled the area for both AGMs and finishing ponds. We
quadrupled the area under roof to more than 8,000 square feet.
We added a multi-purpose building for product processing,
packaging and storage that can also
13
<PAGE>
accommodate further increases in production at our current
site. We laid the foundation for a 10,000 square-foot
laboratory that will accommodate expansion of our drug
discovery program.
NEW PLANT BEGINS PRODUCTION AT FULL CAPACITY. While installing
our final processing equipment, we increased our production of
raw product to full capacity. We began to store raw product.
Final processing of the product will be done once equipment
installation is complete.
DAVID TARNAS JOINS BOARD. Mr. Tarnas brings political
experience to our Board of Directors. As a Hawaii State
Representative and Chairman of the House Committee on Ocean
Recreation and Marine Resources, he led many important policy
initiatives in Hawaii until 1998.
PROCESS PATENT IN EUROPE. We were awarded European Patent
Number 0772676 for a "Method of Control of Microorganism Growth
Process." This patent, originally granted in the U.S., was
awarded in Europe under the Patent Cooperation Treaty. It
claims certain processes that operate in our Aquasearch Growth
Module.
MAR: PROCESS PATENT IN U.S. We received U.S. Patent Number 5,882,849
for a "Method of Control of HAEMATOCOCCUS Species Growth
Process." This patent applies to proprietary techniques we use
to grow HAEMATOCOCCUS, our principal source of astaxanthin. We
are pursuing international patents in certain member nations
that are signatories of the Patent Cooperation Treaty.
APR: APPARATUS PATENT IN NORWAY. We were awarded Norwegian Patent
Number 304556 for a "Process and Apparatus for the Production
of Photosynthetic Microbes." This patent not only claims
certain processes, but also certain features of our core
technology, the Aquasearch Growth Module. Originally granted in
Europe, this patent was awarded in Norway under the Patent
Cooperation Treaty.
PRODUCT FORMULATION BEGINS ON OUR FIRST NUTRACEUTICAL PRODUCT.
A large U.S. chemical company began collaborating with us -
under a confidentiality agreement - to formulate an
astaxanthin-rich nutraceutical product.
MAY: PROCESS PATENT IN AUSTRALIA. We were awarded Australian Patent
Number 698772 for a "Method of Control of Microorganism Growth
Process." This patent, originally granted in the U.S., was
awarded in Australia under the Patent Cooperation Treaty.
APPARATUS PATENT IN SOUTH KOREA. We received South Korea Patent
Number 700834 for a "Process and Apparatus for the Production
of Photosynthetic Microbes." Originally granted in Europe, this
patent was awarded in South Korea under the Patent Cooperation
Treaty.
MICROALGAE FOR OUR SECOND NUTRACEUTICAL PRODUCT APPROVED. The
State of Hawaii Department of Agriculture approved our permit
application to import a new microalgae species. This species is
the basis for our second nutraceutical product, planned for
product launch in 2000.
JUN: PROCESSING EQUIPMENT INSTALLED. Our manufacturing process
became fully operational as
14
<PAGE>
final processing equipment came on line.
RECORD ASTAXANTHIN LEVELS ACHIEVED. We achieved an astaxanthin
content of more than 3% in our final processed product -
sustained over the previous three months. This content is at
least double the amount claimed by any other known producer of
natural astaxanthin. Some of our production runs approached 4%
content, and we achieved 6% content at smaller scales.
JUL: WE BEGIN SHIPPING NATURAL ASTAXANTHIN to a European life
sciences company.
SEP: WE BEGIN SHIPPING NATURAL ASTAXANTHIN to a Japanese life
sciences company.
DEC: THE U.S. DISTRICT COURT FOR THE DISTRICT OF HAWAII GRANTS
MOTION FOR SUMMARY JUDGMENT IN OUR FAVOR. The Court rules that
Cyanotech infringed our patent, misappropriated our trade
secrets, and breached our joint venture dissolution agreement.
In addition, the Court denied Cyanotech's motion for partial
summary judgment of non-infringement and patent invalidity.
2000
JAN: CYANOTECH FILES MOTION FOR RECONSIDERATION on the Court's
summary judgment order.
MAR: THE U.S. DISTRICT COURT FOR THE DISTRICT OF HAWAII DENIES
CYANOTECH'S MOTION FOR RECONSIDERATION. The Court upholds its
summary judgment ruling and denies all reconsideration requests
made by Cyanotech.
WE COMMENCED SALES OF OUR ASTAXANTHIN PRODUCT, THE
ASTAFACTOR-TM-.
DR. SAMUEL LOCKWOOD APPOINTED AS DIRECTOR OF MEDICAL AFFAIRS.
Dr. Lockwood, a research physician and former practicing
clinician at the University of Texas Health Science Center,
will coordinate clinical trials on our products and serve as
the chief medical liaison to the biopharmaceutical industry.
MAY: WE ENTERED INTO A MARKETING AGREEMENT WITH PMP PUBLIC AFFAIRS
CONSULTING, INC. Under the agreement, PMP will lead a targeted
marketing effort for The AstaFactor-TM- patterned after a
patient group strategy well-known and proven in the
biotechnology industry.
www.astaxanthin.org WEBSITE LAUNCHED. The new website provides
comprehensive, up-to-date reviews of the scientific and medical
information on astaxanthin, its properties, and possible
applications for human health.
JUN: $10 MILLION FINANCING COMMITMENT SECURED. An equity line for up
to $10 million is secured from Alpha Venture Capital, Inc., a
$750 million private equity fund group. The equity line can be
drawn against based upon a formula relating to the volume of
trading and price of our common stock.
JUL: WE RECEIVE AN AWARD FROM THE U.S. DEPARTMENT OF ENERGY. The
$2.4 million project will utilize our AGM technology as the
basis of an innovative approach to capture and store gases that
cause the "greenhouse effect." We will team with Physical
Sciences, Inc.
15
<PAGE>
of Andover, Mass. and the Hawaii Natural Energy Institute at
the University of Hawaii on the project.
AUG: OUR FIRST DRUG DISCOVERY LIBRARY IS COMPLETED in collaboration
with EnzyMed, Inc., a division of Albany Molecular Research,
Inc. The National Cancer Institute will be screening the
library, consisting of a novel set of compounds derived from
astaxanthin, for activity in sixty human tumor cell lines,
including tests for activity against lung, colon, melanoma,
prostate, ovarian, breast, and kidney cancers.
WE INITIATE A CLINICAL TRIAL OF ASTAXANTHIN EFFICACY IN
CARDIOVASCULAR DISEASE. The trial, conducted at the Thoracic &
Cardiovascular Healthcare Foundation in Lansing, Michigan, will
evaluate astaxanthin's ability to reduce blood serum levels of
C-reactive protein, the single strongest predictor of risk of
future cardiovascular events in apparently healthy men and
women.
WE INITIATE AN IN VITRO STUDY TO INVESTIGATE THE ROLE OF
ASTAXATHIN IN EYE HEALTH. The six-month in vitro study will be
conducted at the Eye Research Institute at Oakland University
in Rochester, Michigan.
CYANOTECH FILES A MOTION FOR PARTIAL SUMMARY JUDGMENT of
invalidity of the 5,541,056 Patent. We will oppose this motion
which is currently scheduled to be heard on October 16, 2000.
THE MARINE BIOTECHNOLOGY INDUSTRY
There are 30,000 species of microalgae. Many of these are known to contain
valuable substances, including pharmaceuticals, nutraceuticals, and certain
commodities. Fewer than one-tenth of one percent of these 30,000 species have
been produced commercially.
The total market for only three species of microalgae that are now produced
commercially (SPIRULINA, CHLORELLA and HAEMATOCOCCUS) is estimated to be in the
range of $200-300 million per year. We believe the potential market for products
derived from microalgae could range into the billions of dollars, provided that:
(1) the products are unique, valuable, and numerous; and (2) production
technology is reliable and cost-effective.
Scientific literature demonstrates that:
- microalgae contain unique substances;
- these unique substances are potentially valuable as pharmaceuticals
and nutraceuticals; and
- these unique substances are numerous among the microalgae.
Until recently, however, there was no technology to provide for the
cost-effective production of microalgae in commercial quantities. We believe
that our AGM provides reliable and cost-effective production technology that
will contribute to the development of a multi-billion dollar marine
biotechnology industry. However, there can be no assurance that such an industry
will develop.
OUR KEY ACHIEVEMENTS
(1) RELIABLE AND COST EFFECTIVE PRODUCTION TECHNOLOGY
16
<PAGE>
The Aquasearch Growth Module is a novel, reliable and cost-effective production
technology. We have proven the efficacy of the AGM through a 10-year process of
engineering, development, and demonstration.
We continue to achieve targeted improvements in AGM technology and performance,
as this table shows:
<TABLE>
<CAPTION>
-------------------------------------------- ---------------------------------- ----------------------------------
IMPROVEMENT PLANNED IN THE ACHIEVED IN THE
PAST YEAR PAST YEAR
-------------------------------------------- ---------------------------------- ----------------------------------
<S> <C> <C>
Increase AGM size 6X Greater than 6X
Decrease capital cost 2X 3X
(per gallon capacity)
Increase AGM production cycle 30 days 60 days
HAEMATOCOCCUS production rate Increase 3X Greater than 3X
Astaxanthin content of product 2.0% of dry weight Greater than 3.0% of dry weight
-------------------------------------------- ---------------------------------- ----------------------------------
</TABLE>
These improvements to the AGM have reduced costs and increased productivity. We
believe the AGM is the largest commercial photobioreactor in operation. To our
knowledge, our current HAEMATOCOCCUS production rate is higher than any reported
in the scientific literature.
(2) INTELLECTUAL PROPERTY
We now have patents relating to:
- the AGM apparatus (Europe, Australia, Norway, Hong Kong, South
Korea);
- general processes for cultivating microalgae in photobioreactors
(U.S., Europe, Australia); and
- specific processes for cultivating HAEMATOCOCCUS (U.S.).
Additional patents are pending.
We continue to develop trade secrets. We believe that our trade secrets are the
underlying reason for consistent improvements in production and product quality.
We place great value on our intellectual property.
(3) PRODUCTION CAPACITY
In the past year we expanded our physical plant by a factor of three. We now
have a completely new manufacturing plant. The plant includes new processing
equipment and an upgraded process-control system.
Our HAEMATOCOCCUS cultivation process is done in two steps. We use two types of
large-scale production systems: (1) Aquasearch Growth Modules, and (2)
"finishing" ponds. The following table shows the key
17
<PAGE>
features of these two production systems:
<TABLE>
<CAPTION>
------------------------ --------------------------------------------- ---------------------------------------------
FEATURE AQUASEARCH GROWTH MODULE FINISHING POND
------------------------ --------------------------------------------- ---------------------------------------------
<S> <C> <C>
Function Produce HAEMATOCOCCUS biomass Convert biomass to astaxanthin
Technology Proprietary Public domain
Utilized capacity 20% 100%
------------------------ --------------------------------------------- ---------------------------------------------
</TABLE>
We have achieved much greater improvements in AGM performance than anticipated.
As a result, we are now using only 20% of our AGM production capacity. If the
market demands, we could increase total production by 5 times by increasing our
finishing pond capacity. Relative to AGMs, finishing ponds are less costly to
construct.
(4) SALES
We completed construction of the expanded facility in February 1999. New
processing equipment was installed in June 1999. Sales began immediately.
(5) PRODUCT PIPELINE
Prior to this year, our pipeline consisted of a single product: natural
astaxanthin for use in animal nutrition. We have now expanded our pipeline to
include:
1) Nutraceuticals
- Natural astaxanthin
- A second microalgae-based product
2) Drug discovery
- Compound libraries
These products are all in active development. The State of Hawaii Department of
Agriculture has approved our import permit for a new species of microalgae that
is the basis of our second nutraceutical product. EnzyMed recently completed our
first compound library which is presently being screened by the National Cancer
Institute.
(6) OUR TEAM
NEW MANAGEMENT. We believe our team is stronger than ever - at all levels.
During the last 20 months, we have added important experience and expertise at
the management level, including Martin Guerin, David Tarnas, Tim Esaki and Dr.
Samuel Lockwood. Together, these individuals bring us new experience and
expertise in:
- international marketing and sales in food and feed industries;
- public/private sector collaboration;
- financial reporting, SEC reporting, and controls; and
- medical affairs and clinical research.
18
<PAGE>
NEW RESEARCH SCIENTISTS. Dr. Walter Nordhausen, Dr. Mai Lopez, and Dr. Mia Unson
have joined our research team in the last 20 months. Together, they more than
double our research effort, and bring us proven experience in:
- biopharmaceutical product development;
- marine biology and biochemistry;
- natural products chemistry; and
- research program management.
EMPLOYEES. We believe our employees are strongly motivated for success. In 1998
we introduced a pay-for-performance compensation plan that includes both stock
options and cash bonus programs. We structured the compensation plan to reward
both teamwork and individual excellence. Rewards are generated by performance on
quarterly targets. We believe that our employees are directly responsible for
our recent achievements.
(7) RECENT FINANCING ACTIVITY
On June 14, 2000, we entered into a common stock purchase agreement with Alpha
Venture Capital, Inc., a Cook Islands corporation, under which we have agreed to
sell and Alpha has agreed to purchase up to $10 million of our common stock. We
have reserved a total of 20 million shares of our common stock for issuance
pursuant to the purchase agreement and filed a registration statement on July
13, 2000 with the SEC covering the resale of the common stock purchased by Alpha
Venture Capital. We are under no obligation to use the equity line. No draws
have been made on the equity line as of September 14, 2000.
During the period from June 1997 to July 31, 2000, we sold an aggregate of
$8,193,863 principal amount of convertible notes bearing interest at 10% per
annum. The holders of the convertible notes have an option to convert their
convertible notes into our common stock. The convertible notes provide that upon
conversion, the holders would receive warrants to purchase shares of our common
stock. The warrants have exercise prices ranging from $0.50 to $2.00 per share
and a term of three years. As part of this transaction, an officer/director
purchased $2,030,000 of convertible notes.
Through July 31, 2000, some of the holders of the convertibles notes (amounting
to $8,168,863 aggregate principal amount) exercised their option to convert
their convertible notes into shares of common stock. Upon conversion of the
outstanding principal and interest on the convertible notes, we issued
44,776,823 shares of common stock and also issued 7,955,137 warrants in
connection thereto. As part of this transaction, an officer/director converted
$2,030,000 aggregate principal amount of convertible notes and received
13,286,154 shares of common stock and 1,427,000 warrants.
During the quarter ended July 31, 2000, we issued $250,000 aggregate principal
amount of one-year notes payable to an officer of the Company. The notes are
unsecured and bear interest at 10% per annum payable at maturity.
MANAGEMENT'S PLAN OF OPERATION FOR THE NEXT TWELVE MONTHS
Last year we focused on technology and infrastructure. We strengthened our
intellectual property, expanded our physical plant, and augmented production
capacity.
During the next twelve months we will focus on sales and product development,
specifically:
19
<PAGE>
- developing sales of our first nutraceutical product, THE
ASTAFACTOR-TM-;
- formulating our second nutraceutical product;
- growing sales of AQUAXAN-TM-;
- marketing and selling compound libraries for drug discovery; and
- expanding our product pipeline.
(1) THE ASTAFACTOR-TM- - NUTRACEUTICAL ASTAXANTHIN
THE PRODUCT. Our first major nutraceutical product is a dietary supplement rich
in astaxanthin. Astaxanthin is a powerful, bioactive anti-oxidant (approximately
100 times more potent than Vitamin E). Astaxanthin has demonstrated efficacy in
animal or human models of:
- ALZHEIMER'S AND PARKINSON'S DISEASES: major neurodegenerative
diseases
- MACULAR DEGENERATION: the leading cause of blindness in the U.S.
- CHOLESTEROL DISEASE: ameliorates the effects of LDL (the "bad"
cholesterol)
- STROKE: repairs damage caused by lack of oxygen
- CANCER: protects against several types of cancer
THE MARKET. We believe a strong market could develop for THE ASTAFACTOR-TM-
among persons afflicted with these ailments because of:
- LARGE SIZE OF POTENTIAL MARKET: millions of Americans are affected
- POOR PROGNOSIS: some of these diseases have ineffective or no
approved treatments
- PROMISING DATA: quality of data in relevant human and animal models
is promising
Our analysis of reasonable dosage and customary pricing in the nutraceutical
industry suggests that nutraceutical astaxanthin will retail for more than
$50,000 per kilogram. If this estimate proves to be accurate, then we estimate
the potential U.S. market may exceed $500 million per year. This estimate is
based on just one of the six diseases described above, and is derived from the
number of persons affected by the condition, as estimated by physicians who
provide treatment for the disease, and the conventional price of an appropriate
daily dosage. Certain consumers may be highly motivated to use nutraceutical
astaxanthin because:
- treatment alternatives do not exist for some ailments; and
- sufferers have used nutraceuticals with less demonstrated efficacy
than astaxanthin.
PRODUCTION CAPACITY. Our current production capacity would satisfy approximately
1% of the estimated U.S. market for persons affected by just one of the
illnesses mentioned above. We estimate this would generate retail sales of more
than $5 million per year. We currently have plans to expand our production
facility at a new site. The first phase would involve constructing more
finishing ponds, which would result in an expansion of our current production
capacity by a factor of five. We estimate this first phase would cost
approximately $1.8 million. The second phase is still in the general planning
stage and involves construction of a new stand-alone production facility. The
modular nature of the AGM-based production system lends itself well to expansion
at any foreseeable scale. We believe that the experience gained in our recent
plant expansion will make it easier for us to expand our capacity at another
site.
PRODUCT FORMULATION. We are collaborating in product formulation with a large
U.S. chemical company that has significant experience in nutraceutical products.
Our collaboration is being carried out under a
20
<PAGE>
confidentiality agreement. However, we cannot guarantee that our collaboration
will extend beyond product formulation.
MARKETING STRATEGY. We intend to sell this product directly to consumers.
However, several wholesale purchasers of nutraceutical products have also
contacted us regarding our product. We may or may not enter into supply
agreements with one or more wholesalers.
REGULATORY ISSUES. The U.S. Food and Drug Administration ("FDA") has primary
regulatory responsiblity in nutraceutical markets. Many regulations apply. The
DSHEA Act of 1994 governs certain conditions of sale of all nutraceutical
products or dietary supplements in the U.S. We submitted a new dietary
supplement application to the FDA in December 1999. According to the DSHEA Act
of 1994, the FDA has 75 days from the date of a new dietary supplement
pre-marketing application to object to its sale. We did not receive any such
objection from the FDA.
COMPETITION. AstaCarotene AB of Sweden produces and sells an astaxanthin-rich
nutraceutical product in Europe that, like ours, is based on HAEMATOCOCCUS
microalgae. AstaCarotene must produce their product in a controlled climate,
rather than in Sweden's natural climate. We believe their cost of production is
significantly higher than ours.
Cyanotech recently began sales of a HAEMATOCOCCUS-based nutraceutical. Cyanotech
advertises its natural astaxanthin product to contain 1.5% astaxanthin. Our
product contains 3%. To produce the same amount of astaxanthin, therefore,
Aquasearch requires only half the HAEMATOCOCCUS production capacity. We
therefore believe our cost of production may be less than Cyanotech's. We also
believe that customers may perceive our 3% product as superior to a 1.5%
product, which could confer a competitive advantage over Cyanotech's product.
Igene Biotechnology, Inc. produces astaxanthin from yeast. The chemical form of
astaxanthin in HAEMATOCOCCUS is the one that prevails in nature, and is
different from that in yeast. We believe the nutraceutical market will view the
prevailing natural form of astaxanthin - from HAEMATOCOCCUS - as superior as its
astaxanthin content is 10 times more than that of yeast.
Itano of Japan produces an astaxanthin extract from Antarctic krill, a marine
microcrustacean. The product is distributed in the U.S. in very small amounts
and at very high prices (greater than $650,000 per kilogram). Krill fishing in
Antarctica is very expensive and highly regulated. Krill fishing vessels must
travel for more than two weeks, at a cost of approximately $50,000 per day
simply to complete the voyage between Japan and the Southern Ocean. Suitably
equipped vessels cost approximately $30 million and typically have a lifetime of
only 20 years. The krill fishery is regulated by the Committee for Conservation
of Antarctic Living Resources, an international body comprised of scientists
from Antarctic Treaty member nations. The krill fishery reached its peak in the
mid-1980s and has since declined.
BASF and Hoffman-LaRoche both produce synthetic astaxanthin from petrochemicals.
Their compound is chemically different than natural astaxanthin. The effect of
the difference has not been studied. However, the natural form of a closely
related antioxidant, Vitamin E, was found by its manufacturer (Eastman Chemical)
to be four times more potent than the synthetic form. We believe the
nutraceutical market shows less interest in synthetic products than in natural
products, and will pay a premium for a natural product.
TIMING OF PRODUCT RELEASE. We commenced sales of THE ASTAFACTOR-TM- on March 30,
2000.
(2) OUR SECOND NUTRACEUTICAL PRODUCT
21
<PAGE>
THE PRODUCT. Our second nutraceutical product is a dietary supplement rich in a
certain carotenoid pro-vitamin. The pro-vitamin is known to perform certain
vital functions in human physiology. Like astaxanthin, it is a potent
anti-oxidant. Like astaxanthin, which has very similar molecular properties, it
is present in trace quantities in certain common foods. Also like astaxanthin,
it is overproduced in certain microalgae.
THE MARKET. We believe the market for this product is similar to that for
nutraceutical astaxanthin. Animal and human models have demonstrated the
efficacy of this product in its effect on certain common illnesses. We believe
the potential market for this product will exceed $100 million per year.
PRODUCTION CAPACITY. In mid-1999 we received approval from the State of Hawaii
Department of Agriculture to import the microalgae that is the basis of our
second nutraceutical product. We began cultivation at AGM (commercial) scale in
October of 1999. We intend to devote approximately six months to optimizing
production in AGMs. Based on our knowledge and observations of this microalgae,
we believe we have enough production capacity to sustain product introduction.
After approximately one year of production, we project that initial sales would
support the cost of expanding our physical plant.
PRODUCT FORMULATION. The pro-vitamin in this product has chemical properties
that are similar to astaxanthin, and therefore we believe the product
formulation would also be very similar. We have not yet conducted any studies on
product formulation.
MARKETING STRATEGY. We intend to market this product directly to consumers,
building on the experience we will have developed with nutraceutical
astaxanthin. We may also sell limited amounts to wholesalers.
REGULATORY ISSUES. We expect this product to be subject to the same regulatory
issues that govern nutraceutical astaxanthin.
COMPETITION. We know of no competition for this product.
TIMING OF PRODUCT RELEASE. We plan to release this product within the next
12 months.
(3) AQUAXAN-TM- - NATURAL ASTAXANTHIN FOR ANIMAL FEED
THE PRODUCT. We have spent several years developing astaxanthin-rich
AQUAXAN-TM-. Astaxanthin is proven to be a vital dietary component in salmon,
trout, red sea bream, and several other species of cultivated seafood products.
In salmon, the primary market, astaxanthin is important as the main source of
their pink flesh color. Recent studies have also demonstrated the importance of
astaxanthin in enhancing the growth rate, vision, and fertility of salmon.
Astaxanthin is routinely used as a feed additive in poultry feeds, for the
purpose of improving the coloration of eggs and reducing the incidence of
infections. Astaxanthin in the diet of swine has been shown to increase
fertility. Several feeding studies with our astaxanthin-rich microalgae in fish
diets have produced the desired results.
THE MARKET. The market for astaxanthin in aquaculture has grown at about 10% per
year over the past 15 years. The markets for astaxanthin in feeds for poultry,
swine, and other domestic animals are not yet well developed, and are much
smaller. The 1998 global market for astaxanthin was estimated at approximately
$185 million. The sales price for astaxanthin has remained at about $2,500 per
kilogram for the past decade. Consumers in certain niche markets are willing to
pay a premium price. Global annual consumption of astaxanthin is in excess of
65,000 kilograms. Almost all astaxanthin is consumed
22
<PAGE>
in five countries which are, in order of importance, Norway, Chile, Scotland,
Canada and Japan.
PRODUCTION CAPACITY. Our current production capacity amounts to less than 1.0%
of the global market. We plan to increase production capacity only in response
to demand. We have the option to increase capacity in two phases. The first
phase would involve constructing more finishing ponds, which would result in an
expansion of our current production capacity by a factor of five. We estimate
this first phase would cost approximately $1.8 million and could generate annual
sales approaching $2.0 million, if sold at current animal feed prices. The
second phase is still in the general planning stage and involves construction of
a new stand-alone production facility. The modular nature of the AGM-based
production system lends itself well to expansion at any foreseeable scale. We
believe that the experience gained in our recent plant expansion will make it
easier for us to expand our capacity at another site.
PRODUCT FORMULATION. Any feed ingredient, including astaxanthin-rich microalgae,
requires careful formulation and testing prior to market. Our primary goal has
been to create a product that is at least equal, if not superior to, competitive
feed ingredients. We have focused on creating a product with longer shelf life
that is safer and easier to handle, and produces a better result in the diet. We
believe we have achieved these goals. We also believe that further improvement
is possible. If significant changes are made in product formulation, then new
regulatory approvals may have to be obtained. Therefore, we have been very
careful to develop our product to a high standard before placing it on the
market.
MARKETING STRATEGY. We believe that astaxanthin-rich microalgae will account for
a very significant share of the global astaxanthin market. We intend to be a
leader in this market for the following reasons:
1) A SUPERIOR PRODUCT. We believe a product that is safer, easier
to handle, has a longer shelf life, and provides equal or greater
efficacy per unit cost will eventually take significant market
share.
2) CONSUMER AWARENESS. Farmed salmon now account for almost 40% of
global salmon production. Consumers are generally not aware that
the farmed salmon they eat contain a synthetic,
petrochemical-based coloring. Recent studies by the U.S. FDA have
shown that farmed salmon are easily distinguished from wild salmon
because they do not contain the natural form of astaxanthin. All
other factors being equal, we believe that informed consumers will
generally prefer a natural astaxanthin product over a synthetic
one.
The former lead manager of sales and marketing of astaxanthin at Cultor, Martin
Guerin, is now our VP, Sales and Marketing. We recently re-negotiated our
Distribution and Development Agreement with Cultor.
REGULATORY ISSUES. All feed ingredients are regulated in the countries where
they are sold. Regulations differ among astaxanthin-consuming nations. Product
specifications may differ, the stringency of regulations may differ, and the
time required for the application process may differ. In Europe, for example, we
expect regulatory approval could take up to three years, whereas in Chile we
expect such approval should take substantially less time.
COMPETITION. AQUAXAN-TM- competes directly with only one product produced from
HAEMATOCOCCUS microalgae, NATUROSE-TM-, manufactured and sold by Cyanotech.
NATUROSE-TM- is advertised to contain 1.5% astaxanthin. AQUAXAN-TM- contains 3%
astaxanthin.
TIMING OF PRODUCT RELEASE. We began our first sales of AQUAXAN-TM- in July
1999.
(4) DRUG DISCOVERY LIBRARIES
23
<PAGE>
THE DRUG DISCOVERY PROCESS. A large number of modern medicines were originally
discovered in plants. The drug discovery process generally starts by identifying
a plant that has "bioactive" properties. The compound responsible for
bioactivity is identified through a sequence of chemical extraction, testing,
and purification. The pure compound is tested, first in animal models and then
in human clinical trials. If the entire process is completed, the result is a
new drug.
In conjunction with EnzyMed, our strategic partner, we have developed a drug
discovery process adapted to microalgae. Our role in this process is to (1)
identify and cultivate bioactive microalgae species, and (2) chemically extract,
test, and purify the bioactive fractions. Our tests rely on cell cultures, human
tissue cultures and genomic screens, conducted in collaboration with certain
university research laboratories. Bioactive fractions are then subjected to
Combinatorial Biocatalysis, a process which creates, on average, hundreds of
derivative compounds from each pure bioactive compound using EnzyMed's
proprietary enzymatic methods. The resulting Microalgae Compound Libraries are
then ready to market.
THE PRODUCT. Compound libraries are a major source of drug discovery in today's
pharmaceutical industry. The "library" consists of pure compounds, commonly in
sets of 96, packaged in special containers designed for "High-Throughput
Screening." The screening process identifies new drug candidates by testing for
bioactivity, often targeted at certain diseases. Tests might be based on the
ability to kill certain types of cells (e.g. bacteria, cancer), or they might be
based on genetic pathways involved in specific diseases. Any positive result
from a screening test could eventually lead to a new medicine.
We believe the Aquasearch/EnzyMed Microalgae Compound Library is unique because
it has these features:
1) Unexplored resource
- Few microalgae have been screened by the pharmaceutical
industry
2) Quantity
- Species: 30,000
- Bioactive compounds: thousands
- Average derivatives of each bioactive compound: hundreds
via Combinatorial Biocatalysis
3) Possible Patentability
- Bioactive compounds in microalgae may be new to science
- Bioactive derivatives from Combinatorial Biocatalysis may
be new to science
THE MARKET. Consumers of compound libraries are biopharmaceutical companies.
These companies are strongly motivated to find new sources of drugs. According
to a 1997 study by Andersen Consulting, the pharmaceutical industry must
increase its rate of discovery of new drugs by a factor of 10 in five years in
order to maintain its historic growth rate.
Compound libraries are typically marketed as a package that includes the
following terms and conditions:
1) Library Access Fee
- access time: limited to 3-12 months
24
<PAGE>
- application: limited to certain diseases or disease areas
- multiple customers allowed
2) Licensing Fee
- $3 million to $15 million per compound per indication o
activated by decision to begin trials
3) Milestone Payments
- $500,000 to $25 million per event
- activated by the results of pre-clinical and clinical
trials
4) Royalties
- activated by FDA approval and full commercialization
PRODUCTION CAPACITY. We have demonstrated capability in identification,
microalgae cultivation, extraction, purification, and testing of bioactivity.
Our research team includes professional scientists with expertise in all these
areas. However, we have only limited facilities and equipment for chemistry
(extraction, purification) and biochemistry (testing). In these areas, we now
rely on collaborations with several universities and members of our Scientific
Advisory Board. We plan to expand capacity with a 6,000 sq. ft. laboratory
dedicated to drug discovery and appropriate equipment, at an estimated cost of
$2.0 million. Our ability to finance this expansion depends on funds we would
have to raise through revenues, debt or equity.
EnzyMed has demonstrated capability in Combinatorial Biocatalysis. Its contract
customers for this type of "lead optimization" currently include leading
pharmaceutical and biopharmaceutical companies.
MARKETING STRATEGY. Both Aquasearch and EnzyMed have considerable marketing
know-how in the drug discovery market. A number of major pharmaceutical and
biotech companies have already expressed an interest in our first compound
library. Senior officers of both companies are responsible for marketing the
compound libraries.
TIMING OF PRODUCT RELEASE. We released our first library for screening by the
National Cancer Institute in August 2000.
(5) EXPANDING OUR PRODUCT PIPELINE
PRODUCT AREAS. We have established two areas to expand our product pipeline:
- Nutraceuticals
- Pharmaceutical drug development
BASIC STRATEGY: NUTRACEUTICALS. We have identified many potential nutraceutical
products among the microalgae, mostly through the published scientific
literature.
We are focused on markets for high-value products that, like those for natural
astaxanthin and our second nutraceutical product, have potential sales of more
than $100 million, and few or no known competitors. At our recently completed
facility, we can directly measure economic feasibility from data gathered during
a six-month production run in our commercial-scale Ultra-AGM.
25
<PAGE>
We are well aware that nutraceutical products, because they are not highly
regulated, have caused concern among some consumers. Our goal is to
self-regulate at a higher standard than required by law. We are implementing a
variety of testing procedures designed to maximize product safety and product
efficacy.
Our marketing approach may determine many aspects of product development. We
would prefer to sell products directly to the consumer. However, if a strategic
partner can contribute significantly to product development or marketing, then
we will consider an alliance that could accelerate or maximize the process.
BASIC STRATEGY: PHARMACEUTICAL DRUG DEVELOPMENT. Our process for expanding the
pipeline in drug development is firmly founded on strategic collaborations and
alliances. We have strongly leveraged our ability to identify, extract, test,
and purify novel bioactive substances from microalgae through partnerships with
major universities. Additionally, we have enhanced our ability to produce
Microalgae Compound Libraries through our collaboration with EnzyMed.
We are focused in the next year on developing strategic license agreements with
biopharmaceutical companies. We expect many biopharmaceutical companies will be
interested to access our Compound Libraries for drug discovery. We believe our
management team has well-developed networks and relationships in the
biotechnology industry that bring credibility to our marketing approach.
PRODUCT DEVELOPMENT: MARBEC. MarBEC is a 5-year, $26 million Engineering
Research Center funded in 1998 by the U.S. National Science Foundation. There
are fewer than two dozen ERCs in the U.S. In 1998, more than 160 universities
competed for only 5 ERCs awarded by the National Science Foundation.
MarBEC combines the expertise of world-leading marine science and ocean
engineering programs at the School of Ocean and Earth Sciences and Technology at
University of Hawaii with the nationally-famous chemical engineering program at
the Department of Chemical Engineering at University of California, Berkeley.
CORE RESEARCH: Discovery and development of new products from microalgae
COST: Industrial Partnership, $20,000 annually
BENEFITS TO AQUASEARCH:
- New research results prior to public disclosure
- Preferential rights to intellectual property
- Privilege to sponsor focused research, resulting in exclusive
intellectual property rights
- Preferred access to specialized and unique facilities and
equipment
- Preferred access to microalgae culture collections
- Membership on Industrial Advisory Board (current members:
Aquasearch, Monsanto, Cargill, Inc. and Cyanotech)
- Opportunity to influence specific research
- Preferential access to student interns
In the first ten years of the ERC program, two dozen centers generated more than
1,000 patents. Industry members in other ERCs have cited the principal benefits
as (1) strategic relationships arising out of the academic/industry network, (2)
access to specialized equipment and facilities, and (3) better educated
26
<PAGE>
ERC graduates.
PRODUCT DEVELOPMENT: OTHER UNIVERSITIES. We are currently negotiating research
agreements with medical schools at four universities. If consummated, these
agreements will strongly leverage our own product development efforts.
CORE RESEARCH: Pre-clinical screening for drug candidates
- Purification of extracts from approximately 1,200 species of
microalgae in 3 years
- Tissue culture screening
- Genomic screening: allows extracts to be tested for effects on
specific diseases
- Genetic control of microalgae biochemistry
- Targets: skin cancer, breast cancer, antivirals, antifungals
COST: Approximately $500,000 per year. Projects range from 1 to 3 years.
BENEFITS TO AQUASEARCH:
- Ownership of intellectual property
- Increases value of drug candidates
We recognize that pre-clinical screening is costly. However, we believe it is a
very cost-effective investment. The industry-standard license fee for one
compound alone would more than double our anticipated investment.
If we are able to enter into agreements with all four universities, we expect to
generate and screen approximately 10,000 extracts over 3 years at a cost of $1.5
million. If our pre-clinical trials yield only one bioactive compound, the
minimum license fee we expect would be $3 million.
We have three options for screening and pre-clinical trials. We can do them
ourselves, with a corporate partner, or with a university partner. The cost of
facilities, equipment and expertise dictates that we work with a partner. The
advantage of the university partners we have chosen is significant, because the
universities perform contract research and we retain ownership of the compounds.
TIMING OF PRODUCT RELEASE. Our pipeline expansion is a process designed to yield
many more products at minimal cost. Our goal is two products per year. The
result could be less, or it could be far greater.
GENERAL ASPECTS OF PLANNED OPERATIONS
We expect to steadily increase revenues from sales of AQUAXAN-TM-. However, we
do not expect this product alone to be profitable, because we intend to reserve
significant production capacity for THE ASTAFACTOR-TM-.
We commenced sales of THE ASTAFACTOR-TM- on March 30, 2000. We anticipate that
we will become profitable within one year of the launch if we hit our sales
targets - with no increase in production capacity. However, there can be no
assurance that this will occur.
Strategic relationships and collaborations will continue to be an important part
of our business strategy. We now have such relationships with EnzyMed, MarBEC
and Cultor. We expect collaborations will expand to include other corporations
and other universities. However, we cannot be certain to maintain existing
partner relationships, nor can we guarantee to develop other successful
relationships.
27
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Since inception, our primary operating activities have consisted of basic
research and development and production process development; recruiting
personnel; purchasing operating assets; and raising capital. From inception
through July 31, 2000, we had an accumulated deficit of approximately $15.2
million. Our losses to date have resulted primarily from costs incurred in
research and development and from general and administrative expenses associated
with operations. We expect to continue to incur operating losses for at least
the next year as we increase the expansion of our product pipeline. We expect to
have quarter-to-quarter and year-to-year fluctuations in revenues, expenses and
losses, some of which could be significant.
We do have a limited operating history. Your assessment of our prospects should
include the technology risks, market risks, expenses and other difficulties
frequently encountered by development stage companies, and particularly
companies attempting to enter competitive industries with significant technology
risks and barriers to entry. We have attempted to address these risks by, among
other things, hiring and retaining highly qualified persons and forging
strategic alliances with companies and universities that complement and leverage
our technical strengths. However, our best efforts cannot guarantee that we will
overcome these risks in a timely manner, if at all.
We are in the process of transition to a full-scale commercial producer of
microalgae products. These changes in our business have placed and will continue
to place significant demands on our management, working capital and financial
and management control systems.
RESULTS OF OPERATIONS
REVENUES. Since inception, our main activities have been basic research and
development and manufacture process development; recruiting personnel;
purchasing operating assets; and raising capital. In July 1999 we began to ship
our natural astaxanthin product. During the quarters ended January 31, April 30,
and July 31, 2000, we had revenues of approximately $54,000, $70,000, and
$31,000, respectively, in connection with these shipments. On March 30, 2000 we
began sales of our nutraceutical astaxanthin product and have recognized
approximately $9,000 and $17,000 of initial sales during the quarters ended
April 30 and July 31, 2000, respectively. These amounts have been classified as
other income in the accompanying financial statements, since they are considered
to be incidental to our ongoing research and development activities.
RESEARCH AND DEVELOPMENT COSTS. Research and development costs include salaries,
development materials, plant and equipment depreciation and costs associated
with operating our three-acre research and development/production facility.
Research and development costs increased by approximately $206,000 and $626,000,
or 40% and 52%, during the quarter and nine months ended July 31, 2000 compared
to the quarter and nine months ended July 31, 1999, respectively. The increases
reflect additional costs associated with personnel additions, optimizing the
very large Ultra-AGM, expanding production capacity, development of our
nutraceutical astaxanthin product and expenses incurred in connection with the
development of our drug discovery library. From inception through July 31, 2000,
research and development costs totaled approximately $6.6 million. We expect to
incur significant additional research and development costs in the future.
GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative expenses
consist principally of salaries and fees for professional services. General
and administrative expenses increased by approximately $198,000, or 54%,
during the quarter ended July 31, 2000 compared to the quarter ended
28
<PAGE>
July 31, 1999. The increase was primarily due to personnel additions, legal
fees incurred in protecting our intellectual property and costs related to
our initial marketing efforts of The AstaFactor(TM). General and
administrative expenses decreased by approximately $143,000, or 10%, during
the nine months ended July 31, 2000 compared to the nine months ended July
31, 1999. The decline was primarily due to a decrease in legal fees incurred
in connection with our legal dispute with Cyanotech. From inception through
July 31, 2000, general and administrative expenses totaled approximately $6.8
million. We anticipate that general and administrative expenses will increase
over time as we continue expanding our production capacity, develop more new
products, increase our intellectual property protection, and raise additional
capital.
INTEREST EXPENSE. Interest expense for the quarters ended July 31, 2000 and 1999
included $67,070 and $75,882, respectively, for the discount resulting from the
difference between the conversion price and the fair value of the common stock
underlying the convertible notes issued during those quarters. Interest expense
for the nine months ended July 31, 2000 and 1999 included $362,482 and $441,141,
respectively, for the discount resulting from the difference between the
conversion price and the fair value of the common stock underlying the
convertible notes issued during those periods.
LIQUIDITY AND CAPITAL RESOURCES
We have financed our operations until now through public and private sales of
debt and equity securities. In the past nine months, we raised approximately
$2.8 million from the sale of shares of common stock and the issuance of debt in
private placement transactions. From inception through July 31, 2000, we raised
a total of approximately $15.3 million through public and private sales of
equity and debt securities.
During the nine months ended July 31, 2000, operating activities consumed
approximately $2.6 million compared with $2.3 for the nine months ended July 31,
1999. From inception through July 31, 2000, operating activities have consumed
approximately $10.8 million. Capital expenditures from inception through July
31, 2000 totaled approximately $3.9 million.
As of July 31, 2000, our liquidity was approximately $136,000 in cash.
We estimate a need for approximately $3.6 million in operating capital over the
next twelve months. We need an additional $0.5 million to consummate strategic
research agreements with four university medical schools. Projected product
sales will begin to pay some operating costs. We now believe that product sales
could lead to profitability within twelve months after the start of sales of The
AstaFactor-TM-, and that some future expansion could be financed out of profits.
In the near term, we believe that existing capital resources including the $10
million financing commitment from Alpha Venture Capital, Inc., funds raised
through public and/or private offerings of equity and/or debt securities and
bank financing will be sufficient for continued operations through the next
twelve months.
We cannot guarantee success in raising the future capital necessary to sustain
or expand our operations, nor are we certain that such capital will be available
on terms that prevent substantial dilution to existing investors. If we cannot
raise sufficient capital, then we might be forced to significantly curtail
operations. Any reduction in operating activity could have a material adverse
effect on our business, financial condition, results of operations, and
relationships with corporate partners. See "Factors That May Affect Future
Operating Results" in the October 31, 1999 Form 10-KSB.
29
<PAGE>
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
On July 13, 1998, Cyanotech filed a complaint against us in the United States
District Court for the District of Hawaii (Case No. CV98-00600ACK). In the
complaint, Cyanotech sought declaratory judgment of non-infringement of our U.S.
Letters Patent No. 5,541,056; invalidity of the 5,541,056 Patent; and
non-misappropriation of our trade secrets relating to closed culture production
of astaxanthin. Cyanotech filed the complaint after we expressed to Cyanotech
our concern that Cyanotech infringed the 5,541,056 Patent and misappropriated
our trade secrets.
On September 11, 1998, we filed an answer denying all of Cyanotech's allegations
and a counter claim, alleging infringement of the 5,541,056 Patent;
misappropriation of trade secrets; unfair competition; and breach of contract
relative to the parties' 1994 Dissolution Agreement.
On December 14, 1998, Cyanotech filed a motion for partial summary judgment of
non-infringement and invalidity of the 5,541,056 Patent.
On March 1, 1999, we filed a motion for partial summary judgement against
Cyanotech for breach of contract and misappropriation of trade secrets. On
March 26, 1999, we filed a cross-motion for summary judgment of patent
infringement. All motions for summary judgment were heard in November 1999.
On December 30, 1999, the United States District Court for the District of
Hawaii granted summary judgment on our motion that Cyanotech infringed the our
patent, misappropriated our trade secrets and breached the terms of the parties'
1994 Dissolution Agreement. In its order, the Court found that the tube process
used by Cyanotech for cultivating microalgae infringed the 5,541,056 Patent. The
Court further found that Cyanotech violated the Uniform Trade Secrets Act and
breached the 1994 Dissolution Agreement when it misappropriated trade secrets
relating to our proprietary closed-system technology for cultivation of
microalgae.
In addition, the Court denied Cyanotech's motion for partial summary judgment of
non-infringement and invalidity of our patent. In doing so, the Court upheld the
validity of the 5,541,056 Patent.
On January 14, 2000, Cyanotech filed a motion for reconsideration on the Court's
December 30, 1999 order. We filed our opposition to the motion for
reconsideration on February 1, 2000.
On March 3, 2000, the Court denied Cyanotech's motion for reconsideration.
On May 25, 2000, the Court granted our motion to compel Cyanotech to produce
documents related to its BioDome system, financial information relating to its
astaxanthin production, and communications with third parties concerning the
lawsuit. In its order, the Court determined that the information sought on the
BioDome could be relevant in the litigation and could potentially bear on the
remedies or the extent of the patent infringement and trade secret
misappropriations by Cyanotech.
On August 29, 2000, Cyanotech filed a motion for partial summary judgment of
invalidity of the 5,541,056 Patent. We will oppose this motion which is
currently scheduled to be heard on October 16, 2000.
We may be required to dedicate significant management time and incur significant
legal fees and expenses to continue our pursuit and settlement of this action,
which could have a material adverse effect
30
<PAGE>
on our business, financial condition, results of operations and relationships
with corporate partners. In addition, in the event that Cyanotech were to
prevail, a finding of noninfringement or declaration of invalidity of our patent
could have a material adverse effect on our business, financial condition,
results of operations and relationships with corporate partners.
ITEM 2. CHANGES IN SECURITIES
During the quarter ended July 31, 2000, we issued $380,063 aggregate principal
amount of one-year convertible notes bearing interest at 10% per annum. The
holders of the convertible notes have an option to convert their convertible
notes into our common stock. The convertible notes provide that upon conversion,
the holders would receive warrants to purchase shares of our common stock. The
warrants have exercise prices ranging from $0.50 to $1.00 per share and a term
of three years. During the quarter ended July 31, 2000, some of the holders of
these convertibles notes and other outstanding convertible note holders
(amounting to $720,063 aggregate principal amount) exercised their option to
convert their convertible notes into shares of common stock. Upon conversion of
the outstanding principal of, and interest on, the convertible notes, we issued
2,462,193 shares of common stock and also issued 1,106,956 warrants in
connection thereof.
These transactions were exempt from registration under the Securities Act of
1933 pursuant to Section 4(2). No underwriters were involved in these
transactions.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES -- None
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS -- None
ITEM 5. OTHER INFORMATION -- None
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) EXHIBITS -- 10.6$$ Common Stock Purchase Agreement (including
Form of Warrant) Between Alpha Venture
Capital, Inc. and Aquasearch, dated
June 14, 2000.
10.7$$ Registration Rights Agreement between
Alpha Venture Capital, Inc. and
Aquasearch, dated June 14, 2000.
27 Financial Data Schedule
$$ Incorporated by reference to the exhibit
filed with our registration statement on
Form SB-2 filed July 13, 2000.
(b) REPORTS ON FORM 8-K -- None
31
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Quarterly Report on Form 10-QSB to be signed on
its behalf by the undersigned thereunto duly authorized.
AQUASEARCH, INC.
Dated: September 14, 2000 By: /s/ Mark E. Huntley
-------------------------------------
Mark E. Huntley, Ph.D.
President and Chief Executive Officer
By: /s/ Earl S. Fusato
-------------------------------------
Earl S. Fusato
Chief Financial Officer
32
